



An Independent Licensee of the Blue Cross Blue Shield Association

EVIDENCE-BASED CRITERIA
SECTION: SURGERY

ORIGINAL EFFECTIVE DATE: 09/19/22
LAST REVIEW DATE: 09/03/24
CURRENT EFFECTIVE DATE: 09/03/24
LAST CRITERIA REVISION DATE: 09/21/23
ARCHIVE DATE:

NEXT ANNUAL REVIEW DATE: 3RD QTR 2025

MAGNETIC RESONANCE IMAGING-GUIDED FOCUSED ULTRASOUND

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Evidence-Based Criteria must be read in its entirety to determine coverage eligibility, if any.

This Evidence-Based Criteria provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines.

The section identified as "Description" defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage.

The section identified as "Criteria" defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational.

State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity.

Evidence-Based Criteria are subject to change as new information becomes available.

For purposes of this Evidence-Based Criteria, the terms "experimental" and "investigational" are considered to be interchangeable.

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.



An Independent Licensee of the Blue Cross Blue Shield Association

**EVIDENCE-BASED CRITERIA
SECTION: SURGERY**

**ORIGINAL EFFECTIVE DATE: 09/19/22
LAST REVIEW DATE: 09/03/24
CURRENT EFFECTIVE DATE: 09/03/24
LAST CRITERIA REVISION DATE: 09/21/23
ARCHIVE DATE:**

NEXT ANNUAL REVIEW DATE: 3RD QTR 2025

MAGNETIC RESONANCE IMAGING-GUIDED FOCUSED ULTRASOUND

Description:

An integrated system providing magnetic resonance-guided focused ultrasound (MRgFUS) treatment is proposed as a noninvasive therapy for uterine fibroids and pain palliation of bone metastases. MRgFUS is also being investigated as a treatment of other benign and malignant tumors as well as essential tremors.

Magnetic Resonance-Guided Focused Ultrasound

Magnetic resonance-guided focused ultrasound (MRgFUS) is a noninvasive treatment that combines 2 technologies: focused ultrasound and magnetic resonance imaging (MRI). The ultrasound beam penetrates through the soft tissues and, using MRI for guidance and monitoring, the beam can be focused on targeted sites. Ultrasound causes a local increase in temperature in the target tissue, resulting in coagulation necrosis while sparing the surrounding normal structures. Ultrasound waves from each sonication are directed at a focal point that has a maximum focal volume of 20 mm in diameter and 15 mm in height/length. This causes a rapid rise in temperature (e.g., to 65°C-85°C), which is sufficient to ablate tissue at the focal point. In addition to providing guidance, the associated MRI can provide online thermometric imaging, a temperature "map", to confirm the therapeutic effect of the ablation treatment and allow for real-time adjustment of the treatment parameters.

The U.S. Food and Drug Administration (FDA) approved the ExAblate® MRgFUS system for 4 indications: treatment of uterine fibroids (leiomyomata), palliation of pain associated with tumors metastatic to bone, medication refractory ET, and tremor-dominant PD. The ultrasound equipment is specifically designed to be compatible with magnetic resonance magnets, and it is integrated into standard clinical MRI units; it also includes a individual table, which has a cradle that houses the focused ultrasound transducer in water or a light oil bath. Some models have a detachable cradle; only certain cradle types can be used for palliation of pain associated with metastatic bone cancer. For treating pain associated with bone metastases, the aim of MRgFUS is to destroy nerves in the bone surface surrounding the tumor.

MRgFUS is also being investigated for the treatment of other tumors, including breast, prostate, brain, and desmoid tumors as well as nonspinal osteoid osteoma.

Essential Tremors

Essential tremor (ET) is the most common movement disorder, with an estimated prevalence of 5% worldwide. Essential tremor most often affects the hands and arms, may affect head and voice, and rarely includes the face, legs, and trunk. Essential tremor is heterogeneous among individuals, varying in frequency, amplitude, causes of exacerbation, and association with other neurologic deficits.

EVIDENCE-BASED CRITERIA
SECTION: SURGERY

ORIGINAL EFFECTIVE DATE: 09/19/22
LAST REVIEW DATE: 09/03/24
CURRENT EFFECTIVE DATE: 09/03/24
LAST CRITERIA REVISION DATE: 09/21/23
ARCHIVE DATE:

NEXT ANNUAL REVIEW DATE: 3RD QTR 2025

MAGNETIC RESONANCE IMAGING-GUIDED FOCUSED ULTRASOUND

Criteria:

- Magnetic resonance-guided high-intensity ultrasound ablation for pain palliation in adults with metastatic bone cancer who have failed or are not candidates for radiotherapy is considered **medically necessary**.
- Magnetic resonance-guided high-intensity ultrasound ablation for the treatment of medicine-refractory essential tremors is considered **medically necessary**.
- Magnetic resonance-guided high-intensity ultrasound ablation for all other indications not previously listed or if above criteria not met is considered **experimental or investigational** when any **ONE** or more of the following criteria are met:
 1. Lack of final approval from the appropriate governmental regulatory bodies (e.g., Food and Drug Administration); or
 2. Insufficient scientific evidence to permit conclusions concerning the effect on health outcomes; or
 3. Insufficient evidence to support improvement of the net health outcome; or
 4. Insufficient evidence to support improvement of the net health outcome as much as, or more than, established alternatives; or
 5. Insufficient evidence to support improvement outside the investigational setting.

These indications include, *but are not limited to*:

- Treatment of uterine fibroids
- Treatment of other tumors (e.g., brain cancer, prostate cancer, breast cancer, desmoid)
- Treatment of medication-refractory tremor dominant Parkinson disease

Resources:

Literature reviewed 09/03/24. We do not include marketing materials, poster boards and non-published literature in our review

Resources prior to 09/03/24 may be requested from the BCBSAZ Medical Policy and Technology Research Department.

1. American College of Radiology. ACR Appropriateness Criteria: Management of Uterine Fibroids. Updated 2023. Accessed May 15, 2024. <https://acsearch.acr.org/docs/69508/Narrative/>.
2. Arrigoni F, Barile A, Zugaro L, et al. Intra-articular benign bone lesions treated with Magnetic Resonance-guided Focused Ultrasound (MRgFUS): imaging follow-up and clinical results. *Med Oncol*. Apr 2017;34(4):55. doi:10.1007/s12032-017-0904-7

**EVIDENCE-BASED CRITERIA
SECTION: SURGERY**

**ORIGINAL EFFECTIVE DATE: 09/19/22
LAST REVIEW DATE: 09/03/24
CURRENT EFFECTIVE DATE: 09/03/24
LAST CRITERIA REVISION DATE: 09/21/23
ARCHIVE DATE:**

NEXT ANNUAL REVIEW DATE: 3RD QTR 2025

MAGNETIC RESONANCE IMAGING-GUIDED FOCUSED ULTRASOUND

3. Arrigoni F, Napoli A, Bazzocchi A, et al. Magnetic-resonance-guided focused ultrasound treatment of non-spinal osteoid osteoma in children: multicentre experience. *Pediatr Radiol*. Aug 2019;49(9):1209-1216. doi:10.1007/s00247-019-04426-0
4. Arrigoni F, Spiliopoulos S, de Cataldo C, et al. A Bicentric Propensity Score Matched Study Comparing Percutaneous Computed Tomography-Guided Radiofrequency Ablation to Magnetic Resonance-Guided Focused Ultrasound for the Treatment of Osteoid Osteoma. *J Vasc Interv Radiol*. Jul 2021;32(7):1044-1051. doi:10.1016/j.jvir.2021.03.528
5. Avedian RS, Bitton R, Gold G, Butts-Pauly K, Ghanouni P. Is MR-guided High-intensity Focused Ultrasound a Feasible Treatment Modality for Desmoid Tumors? *Clin Orthop Relat Res*. Mar 2016;474(3):697-704. doi:10.1007/s11999-015-4364-0
6. Baal JD, Chen WC, Baal U, et al. Efficacy and safety of magnetic resonance-guided focused ultrasound for the treatment of painful bone metastases: a systematic review and meta-analysis. *Skeletal Radiol*. Dec 2021;50(12):2459-2469. doi:10.1007/s00256-021-03822-8
7. Barnard EP, AbdElmagied AM, Vaughan LE, et al. Periprocedural outcomes comparing fibroid embolization and focused ultrasound: a randomized controlled trial and comprehensive cohort analysis. *Am J Obstet Gynecol*. May 2017;216(5):500 e1-500 e11. doi:10.1016/j.ajog.2016.12.177
8. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). *Magnetic resonance-guided focused ultrasound therapy for symptomatic uterine fibroids TEC Assessments*. Vol. 20:Tab 10. 2005.
9. Bond AE, Shah BB, Huss DS, et al. Safety and Efficacy of Focused Ultrasound Thalamotomy for Patients With Medication-Refractory, Tremor-Dominant Parkinson Disease: A Randomized Clinical Trial. *JAMA Neurol*. Dec 1 2017;74(12):1412-1418. doi:10.1001/jamaneurol.2017.3098
10. Bucknor MD, Rieke V. MRgFUS for desmoid tumors within the thigh: early clinical experiences. *J Ther Ultrasound*. 2017;5:4. doi:10.1186/s40349-017-0081-3
11. Chang JW, Park CK, Lipsman N, et al. A prospective trial of magnetic resonance-guided focused ultrasound thalamotomy for essential tremor: Results at the 2-year follow-up. *Ann Neurol*. Jan 2018;83(1):107-114. doi:10.1002/ana.25126
12. Chen R, Keserci B, Bi H, et al. The safety and effectiveness of volumetric magnetic resonance-guided high-intensity focused ultrasound treatment of symptomatic uterine fibroids: early clinical experience in China. *J Ther Ultrasound*. 2016;4:27. doi:10.1186/s40349-016-0072-9
13. Eastham JA, Boorjian SA, Kirkby E. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. *J Urol*. Sep 2022;208(3):505-507. doi:10.1097/JU.0000000000002854

**EVIDENCE-BASED CRITERIA
SECTION: SURGERY**

**ORIGINAL EFFECTIVE DATE: 09/19/22
LAST REVIEW DATE: 09/03/24
CURRENT EFFECTIVE DATE: 09/03/24
LAST CRITERIA REVISION DATE: 09/21/23
ARCHIVE DATE:**

NEXT ANNUAL REVIEW DATE: 3RD QTR 2025

MAGNETIC RESONANCE IMAGING-GUIDED FOCUSED ULTRASOUND

14. Ehdai B, Tempany CM, Holland F, et al. MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study. *Lancet Oncol.* Jul 2022;23(7):910-918. doi:10.1016/S1470-2045(22)00251-0
15. Elias WJ, Lipsman N, Ondo WG, et al. A Randomized Trial of Focused Ultrasound Thalamotomy for Essential Tremor. *N Engl J Med.* Aug 25 2016;375(8):730-9. doi:10.1056/NEJMoa1600159
16. Eltoukhi HM, Modi MN, Weston M, Armstrong AY, Stewart EA. The health disparities of uterine fibroid tumors for African American women: a public health issue. *Am J Obstet Gynecol.* Mar 2014;210(3):194-9. doi:10.1016/j.ajog.2013.08.008
17. Expert Panel on Interventional R, Knuttinen MG, Stark G, et al. ACR Appropriateness Criteria((R)) Radiologic Management of Uterine Leiomyomas. *J Am Coll Radiol.* May 2018;15(5S):S160-S170. doi:10.1016/j.jacr.2018.03.010
18. Geiger D, Napoli A, Conchiglia A, et al. MR-guided focused ultrasound (MRgFUS) ablation for the treatment of nonspinal osteoid osteoma: a prospective multicenter evaluation. *J Bone Joint Surg Am.* May 7 2014;96(9):743-51. doi:10.2106/JBJS.M.00903
19. Ghai S, Finelli A, Corr K, et al. MRI-guided Focused Ultrasound Ablation for Localized Intermediate-Risk Prostate Cancer: Early Results of a Phase II Trial. *Radiology.* Mar 2021;298(3):695-703. doi:10.1148/radiol.2021202717
20. Ghai S, Finelli A, Corr K, et al. MRI-guided Focused Ultrasound Focal Therapy for Intermediate-Risk Prostate Cancer: Final Results from a 2-year Phase II Clinical Trial. *Radiology.* Mar 2024;310(3):e231473. doi:10.1148/radiol.231473
21. Ghanouni P, Dobrotwir A, Bazzocchi A, et al. Magnetic resonance-guided focused ultrasound treatment of extra-abdominal desmoid tumors: a retrospective multicenter study. *Eur Radiol.* Feb 2017;27(2):732-740. doi:10.1007/s00330-016-4376-5
22. Gianfelice D, Khiat A, Amara M, Belblidia A, Boulanger Y. MR imaging-guided focused US ablation of breast cancer: histopathologic assessment of effectiveness-- initial experience. *Radiology.* Jun 2003;227(3):849-55. doi:10.1148/radiol.2281012163
23. Gianfelice D, Khiat A, Amara M, Belblidia A, Boulanger Y. MR imaging-guided focused ultrasound surgery of breast cancer: correlation of dynamic contrast-enhanced MRI with histopathologic findings. *Breast Cancer Res Treat.* Nov 2003;82(2):93-101. doi:10.1023/B:BREA.0000003956.11376.5b
24. Giordano M, Caccavella VM, Zaed I, et al. Comparison between deep brain stimulation and magnetic resonance-guided focused ultrasound in the treatment of essential tremor: a systematic review and pooled analysis of functional outcomes. *J Neurol Neurosurg Psychiatry.* Dec 2020;91(12):1270-1278. doi:10.1136/jnnp-2020-323216

**EVIDENCE-BASED CRITERIA
SECTION: SURGERY**

**ORIGINAL EFFECTIVE DATE: 09/19/22
LAST REVIEW DATE: 09/03/24
CURRENT EFFECTIVE DATE: 09/03/24
LAST CRITERIA REVISION DATE: 09/21/23
ARCHIVE DATE:**

NEXT ANNUAL REVIEW DATE: 3RD QTR 2025

MAGNETIC RESONANCE IMAGING-GUIDED FOCUSED ULTRASOUND

25. Gizzo S, Saccardi C, Patrelli TS, et al. Magnetic resonance-guided focused ultrasound myomectomy: safety, efficacy, subsequent fertility and quality-of-life improvements, a systematic review. *Reprod Sci.* Apr 2014;21(4):465-76. doi:10.1177/1933719113497289
26. Health Quality O. Magnetic Resonance-Guided Focused Ultrasound Neurosurgery for Essential Tremor: A Health Technology Assessment. *Ont Health Technol Assess Ser.* 2018;18(4):1-141.
27. Hurwitz MD, Ghanouni P, Kanaev SV, et al. Magnetic resonance-guided focused ultrasound for patients with painful bone metastases: phase III trial results. *J Natl Cancer Inst.* Apr 23 2014;106(5)doi:10.1093/jnci/dju082
28. Hynynen K, Pomeroy O, Smith DN, et al. MR imaging-guided focused ultrasound surgery of fibroadenomas in the breast: a feasibility study. *Radiology.* Apr 2001;219(1):176-85. doi:10.1148/radiology.219.1.r01ap02176
29. Jacoby VL, Kohi MP, Poder L, et al. PROMISe trial: a pilot, randomized, placebo-controlled trial of magnetic resonance guided focused ultrasound for uterine fibroids. *Fertil Steril.* Mar 2016;105(3):773-780. doi:10.1016/j.fertnstert.2015.11.014
30. Laughlin-Tommaso S, Barnard EP, AbdElmagied AM, et al. FIRSTT study: randomized controlled trial of uterine artery embolization vs focused ultrasound surgery. *Am J Obstet Gynecol.* Feb 2019;220(2):174 e1-174 e13. doi:10.1016/j.ajog.2018.10.032
31. Lutz S, Balboni T, Jones J, et al. Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline. *Pract Radiat Oncol.* Jan-Feb 2017;7(1):4-12. doi:10.1016/j.prro.2016.08.001
32. McDannold N, Clement GT, Black P, Jolesz F, Hynynen K. Transcranial magnetic resonance imaging- guided focused ultrasound surgery of brain tumors: initial findings in 3 patients. *Neurosurgery.* Feb 2010;66(2):323-32; discussion 332. doi:10.1227/01.NEU.0000360379.95800.2F
33. Merkel LG, Knuttel FM, Deckers R, et al. First clinical experience with a dedicated MRI-guided high-intensity focused ultrasound system for breast cancer ablation. *Eur Radiol.* Nov 2016;26(11):4037-4046. doi:10.1007/s00330-016-4222-9
34. Miller WK, Becker KN, Caras AJ, et al. Magnetic resonance-guided focused ultrasound treatment for essential tremor shows sustained efficacy: a meta-analysis. *Neurosurg Rev.* Feb 2022;45(1):533-544. doi:10.1007/s10143-021-01562-w
35. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology:Bone Cancer. Verson 2.2024. Accessed May 14, 2024. https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf



An Independent Licensee of the Blue Cross Blue Shield Association

**EVIDENCE-BASED CRITERIA
SECTION: SURGERY**

**ORIGINAL EFFECTIVE DATE: 09/19/22
LAST REVIEW DATE: 09/03/24
CURRENT EFFECTIVE DATE: 09/03/24
LAST CRITERIA REVISION DATE: 09/21/23
ARCHIVE DATE:**

NEXT ANNUAL REVIEW DATE: 3RD QTR 2025

MAGNETIC RESONANCE IMAGING-GUIDED FOCUSED ULTRASOUND

36. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology:Breast Cancer. Version 2.2024. Accessed May 13, 2024. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
37. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology:Central Nervous System Cancers. Version 1.2023. Accessed May 12, 2024. https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
38. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology:Prostate Cancer. Version 3.2024. Accessed May 11, 2024. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
39. National Institute of Health and Care Excellence (NICE). Unilateral MRI-guided focused ultrasoundthalamotomy for treatment-resistant essential tremor [IPG617]. Accessed May 15, 2024. <https://www.nice.org.uk/guidance/ipg617>
40. Otonkoski S, Sainio T, Mattila S, et al. Magnetic resonance guided high intensity focused ultrasound for uterine fibroids and adenomyosis has no effect on ovarian reserve. *Int J Hyperthermia*. 2023;40(1):2154575. doi:10.1080/02656736.2022.2154575
41. Rabinovici J, David M, Fukunishi H, et al. Pregnancy outcome after magnetic resonance-guided focused ultrasound surgery (MRgFUS) for conservative treatment of uterine fibroids. *Fertil Steril*. Jan 2010;93(1):199-209. doi:10.1016/j.fertnstert.2008.10.001
42. Xu F, Deng L, Zhang L, Hu H, Shi Q. The comparison of myomectomy, UAE and MRgFUS in the treatment of uterine fibroids: a meta analysis. *Int J Hyperthermia*. Sep 2021;38(2):24-29. doi:10.1080/02656736.2021.1933216
43. Zippel DB, Papa MZ. The use of MR imaging guided focused ultrasound in breast cancer patients; a preliminary phase one study and review. *Breast Cancer*. 2005;12(1):32-8. doi:10.2325/jbcs.12.32

Coding:

CPT: 0071T, 0072T, 0398T, 55899, 58578, 58999, 77022, 76940
HCPCS: C9734

CPT copyright 2024 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association



An Independent Licensee of the Blue Cross Blue Shield Association

**EVIDENCE-BASED CRITERIA
SECTION: SURGERY**

**ORIGINAL EFFECTIVE DATE: 09/19/22
LAST REVIEW DATE: 09/03/24
CURRENT EFFECTIVE DATE: 09/03/24
LAST CRITERIA REVISION DATE: 09/21/23
ARCHIVE DATE:**

NEXT ANNUAL REVIEW DATE: 3RD QTR 2025

MAGNETIC RESONANCE IMAGING-GUIDED FOCUSED ULTRASOUND

<u>History:</u>	<u>Date:</u>	<u>Activity:</u>
Medical Policy Panel	09/03/24	Review with revisions
Medical Policy Panel	09/21/23	Review with revisions
Medical Policy Panel	08/01/23	Review with no revisions
Medical Policy Panel	08/16/22	Approved guideline (Effective 09/19/22)
Medical Director (Dr. Deering)	07/06/22	Development

Policy Revisions:

09/03/24	Updated:	Resources section
09/21/23	Added:	“Insufficient evidence to support improvement of the net health outcome; or”, and “Insufficient evidence to support improvement of the net health outcome as much as, or more than, established alternatives, or” to experimental or investigational criteria.
09/21/23	Revised:	“Insufficient evidence to support improvement outside the investigational setting” from #3 to #5 in experimental or investigational criteria.
09/21/23	Updated:	Resources section.



An Independent Licensee of the Blue Cross Blue Shield Association

EVIDENCE-BASED CRITERIA
SECTION: SURGERY

ORIGINAL EFFECTIVE DATE: 09/19/22
LAST REVIEW DATE: 09/03/24
CURRENT EFFECTIVE DATE: 09/03/24
LAST CRITERIA REVISION DATE: 09/21/23
ARCHIVE DATE:

NEXT ANNUAL REVIEW DATE: 3RD QTR 2025

MAGNETIC RESONANCE IMAGING-GUIDED FOCUSED ULTRASOUND

Non-Discrimination Statement:

Blue Cross Blue Shield of Arizona (BCBSAZ) complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability or sex. BCBSAZ provides appropriate free aids and services, such as qualified interpreters and written information in other formats, to people with disabilities to communicate effectively with us. BCBSAZ also provides free language services to people whose primary language is not English, such as qualified interpreters and information written in other languages. If you need these services, call (602) 864-4884 for Spanish and (877) 475-4799 for all other languages and other aids and services.

If you believe that BCBSAZ has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability or sex, you can file a grievance with: BCBSAZ's Civil Rights Coordinator, Attn: Civil Rights Coordinator, Blue Cross Blue Shield of Arizona, P.O. Box 13466, Phoenix, AZ 85002-3466, (602) 864-2288, TTY/TDD (602) 864-4823, crc@azblue.com. You can file a grievance in person or by mail or email. If you need help filing a grievance BCBSAZ's Civil Rights Coordinator is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights electronically through the Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, or by mail or phone at: U.S. Department of Health and Human Services, 200 Independence Avenue SW., Room 509F, HHH Building, Washington, DC 20201, 1-800-368-1019, 800-537-7697 (TDD). Complaint forms are available at <http://www.hhs.gov/ocr/office/file/index.html>

Multi-Language Interpreter Services:

Spanish: Si usted, o alguien a quien usted está ayudando, tiene preguntas acerca de Blue Cross Blue Shield of Arizona, tiene derecho a obtener ayuda e información en su idioma sin costo alguno. Para hablar con un intérprete, llame al 602-864-4884.

Navajo: Díí kwe'é atah nilínígíí Blue Cross Blue Shield of Arizona haada yit'éego bina'idílkidgo éí doodago Háida bíjá anilyeedígíí t'áadoo le'é yina'idílkidgo beehaz'áanii hólo díí t'áa hazaadk'ehjí háká a'doowolgo bee haz'ą doo baqah ilínígóó. Ata' halne'ígíí kojí' bich'í' hodílnih 877-475-4799.

Chinese: 如果您，或是您正在協助的對象，有關於插入項目的名稱 Blue Cross Blue Shield of Arizona 方面的問題，您有權利免費以您的母語得到幫助和訊息。洽詢一位翻譯員，請撥電話 在此插入數字 877-475-4799。

Vietnamese: Nếu quý vị, hay người mà quý vị đang giúp đỡ, có câu hỏi về Blue Cross Blue Shield of Arizona quý vị sẽ có quyền được giúp và có thêm thông tin bằng ngôn ngữ của mình miễn phí. Để nói chuyện với một thông dịch viên, xin gọi 877-475-4799.

Arabic:

إن كان لديك أو لدى شخص تساعد أسئلة بخصوص Blue Cross Blue Shield of Arizona، فلديك الحق في الحصول على المساعدة والمعلومات الضرورية بلغتك من دون أية تكلفة. للتحدث مع مترجم اتصل بـ 877-475-4799.

